Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone for locally advanced laryngeal & nasopharyngeal cancers: A retrospective study

Walaa Samir Abdu Ali, Maha Lotfy Zamzam, Ehab Mohammed Hasanin, Sharehan Hassan Soliman

Abstract


Background: One of the most common cancers all over the world is Head and Neck cancers, with higher mortality rates among developing countries. Squamous cell carcinomas (SCCs) represent more than 90%. SCCs arise commonly from the mucosal lining of the upper aerodigestive tract.
Objective: To Compare between Concurrent Chemoradiation following Neoadjuvant Chemotherapy versus Concurrent Chemoradiation alone in Locally Advanced Larynx & Nasopharynx Cancer (stage III or IVA,B) regarding efficacy, toxicity, progression free survival, disease free survival and organ preservation (in laryngeal cancer).
Methods: A Retrospective study was conducted to Compare between Concurrent Chemoradiation following Neoadjuvant Chemotherapy versus Concurrent Chemoradiation alone in Locally Advanced Larynx & Nasopharynx Cancer (stage III or IVA,B) in the Clinical Oncology Department, Suez Canal University Hospital, Ismailia, Egypt between 1/2017 & 12/2018, with follow up 2 years (from 1/2019 to 12/2020).
Results: Results of our study show a statistic significance in progression free survival in Concurrent chemoradiation following neoadjuvant chemotherapy compared with concurrent chemoradiation alone.
Conclusions: Neoadjuvant chemotherapy by TPF or PF is a wise choice in the locally advanced squamous cell carcinoma of the nasopharynx and larynx (non-metastatic cases). Better results were detected in radiological assessment post radiation therapy in laryngeal cancer cases and progression free survival in both treatment groups.

Full Text:

PDF


DOI: https://doi.org/10.5430/jst.v12n1p1

Journal of Solid Tumors

ISSN 1925-4067(Print)   ISSN 1925-4075(Online)

Copyright © Sciedu Press


To make sure that you can receive messages from us, please add the 'Sciedupress.com' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.